We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
- Authors
Vigna, E; De Vivo, A; Gentile, M; Morelli, R; Lucia, E; Mazzone, C; Recchia, A G; Vianelli, N; Morabito, F
- Abstract
Leishmaniasis is a zoonosis caused by a protozoan of the Leishmania genus. First-line treatment for all forms is currently represented by the use of antimony derivatives, although toxic effects and the number of resistant strains in both immunocompromised and immunocompetent patients is increasing. Liposomal amphotericin B (L-AMB) is less toxic, more effective, and better tolerated, especially in human immunodeficiency virus-negative immunocompromised patients. We present 2 cases of transplanted patients affected by visceral leishmaniasis treated successfully with L-AMB.
- Publication
Transplant infectious disease : an official journal of the Transplantation Society, 2010, Vol 12, Issue 5, p428
- ISSN
1399-3062
- Publication type
Journal Article
- DOI
10.1111/j.1399-3062.2010.00519.x